Scottish supplier of clinical-grade pluripotent stem cells announced that it has established a new partnership to allow Pfizer access to its production lines.
The purpose of the agreement is for Pfizer to evaluate the quality of the operations at Roslin Cells in order to ascertain whether or not the stem cell supplier has the potential for “specific clinical therapies”. Roslin Cells noted that it will be the first time its Good Manufacturing Practice (GMP) level cell lines will…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
